Who is sponsoring NCT04516811?

NCT04516811 is sponsored by South African National Blood Service.

What condition does NCT04516811 study?

NCT04516811 studies COVID-19, SARS-CoV-2 Infection, Severe Acute Respiratory Syndrome Coronavirus 2.

Is NCT04516811 still recruiting?

NCT04516811 is currently status unknown. Last updated 25 September 2020.

Last reviewed 2020-09-25 · How we verify

NCT04516811

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Therapeutic Use of Convalescent Plasma in the Treatment of Patients With Moderate to Severe COVID-19

Status unknown Phase 3 Last updated 25 September 2020

What this trial tests

Phase 3 trial testing COVID-19 convalescent plasma (CCP) plus standard of care (SOC) in COVID-19 in 600 participants. Status unknown.

Timeline

21 September 2020

Primary endpoint
30 December 2021

31 July 2022

Quick facts

Lead sponsor	South African National Blood Service
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	600
Start date	21 September 2020
Primary completion	30 December 2021
Estimated completion	31 July 2022
Sites	2 locations across South Africa

Drugs / interventions tested

COVID-19 convalescent plasma (CCP) plus standard of care (SOC) — full drug profile →
Standard of care (SOC) plus placebo — full drug profile →

Conditions studied

COVID-19 — all drugs for COVID-19 →
SARS-CoV-2 Infection — all drugs for SARS-CoV-2 Infection →
Severe Acute Respiratory Syndrome Coronavirus 2 — all drugs for Severe Acute Respiratory Syndrome Coronavirus 2 →

Sponsor

South African National Blood Service — full company profile →

Who can join

18 and older, any sex, with COVID-19 or SARS-CoV-2 Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A prospective, randomized, placebo-controlled, double-blinded, phase III clinical trial of the therapeutic use of convalescent plasma in the treatment of patients with moderate to severe COVID-19

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment.
Drożdżal S, Rosik J, Lechowicz K, Machaj F, et al · · 2021 · cited 186× · PMID 34991982 · DOI 10.1016/j.drup.2021.100794
Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.
Piechotta V, Iannizzi C, Chai KL, Valk SJ, et al · · 2021 · cited 106× · PMID 34013969 · DOI 10.1002/14651858.cd013600.pub4
COVID-19 Convalescent Plasma and Clinical Trials: Understanding Conflicting Outcomes.
Focosi D, Franchini M, Pirofski LA, Burnouf T, et al · · 2022 · cited 79× · PMID 35262370 · DOI 10.1128/cmr.00200-21
COVID-19 convalescent plasma: Interim recommendations from the AABB.
Cohn CS, Estcourt L, Grossman BJ, Pagano MB, et al · · 2021 · cited 38× · PMID 33586160 · DOI 10.1111/trf.16328
Convalescent plasma in the treatment of moderate to severe COVID-19 pneumonia: a randomized controlled trial (PROTECT-Patient Trial).
van den Berg K, Glatt TN, Vermeulen M, Little F, et al · · 2022 · cited 28× · PMID 35169169 · DOI 10.1038/s41598-022-06221-8
Convalescent plasma for people with COVID-19: a living systematic review.
Iannizzi C, Chai KL, Piechotta V, Valk SJ, et al · · 2023 · cited 24× · PMID 36734509 · DOI 10.1002/14651858.cd013600.pub5
Convalescent plasma for people with COVID-19: a living systematic review.
Iannizzi C, Chai KL, Piechotta V, Valk SJ, et al · · 2023 · cited 21× · PMID 37162745 · DOI 10.1002/14651858.cd013600.pub6
Convalescent plasma (hyperimmune immunoglobulin) for COVID-19 management: An update.
Chavda VP, Bezbaruah R, Dolia S, Shah N, et al · · 2023 · cited 10× · PMID 36741339 · DOI 10.1016/j.procbio.2023.01.018

Verify or expand the search:

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04516811 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by South African National Blood Service
Last refreshed: 25 September 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04516811.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing